Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | CCND1 | P24385 | 3/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615313 | 0.83 | AVPR1A (0.70) | DRD2AVPR1A | |
| SCHEMBL6591685 | 0.77 | DRD2 (0.68) | DRD2AVPR1AHTR1A | |
| Oxalic Acid SCHEMBL6595691 | 0.77 | DRD2 (0.81) | DRD2HTR1A | |
| SCHEMBL6589929 | 0.76 | DRD2 (0.89) | DRD2HTR1A | |
| SCHEMBL7533295 | 0.75 | MAPT (0.65) | MAPTCDK4CCND1AVPR1AHTR1A | |
| SCHEMBL3913948 | 0.74 | DRD2 (1.00) | DRD2HTR1A | |
| SCHEMBL11784754 | 0.70 | AVPR1A (0.67) | MAPTCDK4CCND1AVPR1AKDM4E | |
| SCHEMBL6590608 | 0.70 | DRD2 (0.89) | DRD2HTR1A | |
| SCHEMBL1558891 | 0.69 | ALDH1A1 (0.69) | MAPTCDK4CCND1AVPR1AKDM4E | |
| SCHEMBL3914302 | 0.69 | DRD2 (1.00) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | disclosed |
| CN-1515568-A | Indole and 2,3-indoline derivative, their preparation and application | H.隆德贝克有限公司 | 2004-07-28 | — | — | CN | disclosed |
| CN-1515569-A | Indole and 2,3-indoline derivative, their preparation and application | H.隆德贝克有限公司 | 2004-07-28 | — | — | CN | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| CN-1127501-C | indole and 2, 3-indoline derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2003-11-12 | — | — | CN | disclosed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| CN-1265107-A | indole and 2, 3-indoline derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2000-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | DRD2 26/4885MAPT 2725/4885CDK4 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.